書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
辻浩一郎	造血幹細胞並びにサイトカインの基礎と応用	小寺良尚 加藤俊一	必携造血幹細胞移植ーわが国のエビデンスを中心にー	医学書院	東京	2004	21-34
辻浩一郎	造血幹細胞	平井久丸 押味和夫 坂田洋一	血液の辞典	朝倉書店	東京	2004	39-41
辻浩一郎	造血幹細胞と血液の分化	三輪史朗 渡辺陽之輔	血液細胞アトラス	文光堂	東京	2004	30-32
辻浩一郎	小児白血病.	浅野茂隆 池田康夫	白血病はこわくない	丸善	東京	2004	64-75

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K	Human placenta-derived cells have mesenchymal stem/progenitor cell potential.	Stem Cells	22	649-648	2004
Manabe A, Yoshimasu T, Ebihara Y, Yagasaki H, Wada M, Ishikawa K, Hara J, Koike K, Moritake H, Park Y-D, Tsuji K, Nakahata T	Viral infections in juvenile myelomonocytic leukemia: Prevalence and clinical implications.	J Pediatr Hematol Oncol	26	636-641	2004
Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M, Honda K, Shinohara H, Sudo K, Tsuji K, Nakauchi H, Iwakura Y, Hirai H, Oda H, YamamotoT, Yamanashi Y	Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.	J Exp Med	200	1681-1687	2004

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hasegawa D, Manabe A, Kubota T, Kawasaki H, Hirose I, Ohtsuka Y, Tsuruta T, Ebihara Y, Goto Y, Zhao XY, Sakashita K, Koike K, Isomura M, Kojima S, Hoshika A, Tsuji K, Nakahata T	Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia.	Br J Haematol	in press		
長谷川大輔、真部淳、鶴田敏久、大塚欣敏、海老原康博、河崎裕英、有瀧健太郎、松浦恵子、星加明徳、辻浩一郎	CD7/CD13 陽性急性分類不能型白血病.	日小血会誌	18	155-159	2004
河崎裕英、峰研治、野田幸弘、中野崇秀	後天性サイトメガロウイルス感染症小児に合併した免疫学的血小板減少性紫斑病.	日小血会誌	18	561-565	2004
辻浩一郎	ヒト胚性幹細胞からの血液産生と再生医療.	日小血会誌	印刷中		

Ⅳ. 研究成果の刊行物・別冊

STEM CELLS®
Rapid Communication

Human Placenta-Derived Cells Have Mesenchymal Stem/Progenitor Cell Potential

YUMI FUKUCHI, HIDEAKI NAKAJIMA, DAISUKE SUGIYAMA,
IMIKO HIROSE, TOSHIO KITAMURA, KOHICHIRO TSUJI

Division of Cellular Therapy, The Advanced Clinical Research Center,
Institute of Medical Science, The University of Tokyo, Japan

Key Words. Human placenta • Placenta-derived cells • Mesenchymal stem/progenitor cells • Cell culture

ABSTRACT

Mesenchymal stem/progenitor cells (MSCs) are widely distributed in a variety of tissues in the adult human body (e.g., bone marrow [BM], kidney, lung, and liver). These cells are also present in the fetal environment (e.g., blood, liver, BM, and kidney). However, MSCs are a rare population in these tissues. Here we tried to identify cells with MSC-like potency in human placenta. We isolated adherent cells from trypsin-digested term placentas and established two clones by limiting dilution. We examined these cells for morphology, surface markers, gene expression patterns, and differentiation potential and found that they expressed several stem cell markers, hematopoietic/endothelial cell–related genes, and organ-specific genes, as determined by reverse transcription–polymerase chain reaction and fluorescence-activated cell sorter analysis. They also showed osteogenic and adipogenic differentiation potentials under appropriate conditions. We suggest that placenta-derived cells have multilineage differentiation potential similar to MSCs in terms of morphology, cell-surface antigen expression, and gene expression patterns. The placenta may prove to be a useful source of MSCs. *Stem Cells 2004;22:649–658*

INTRODUCTION

Multipotential mesenchymal stem/progenitor cells (MSCs) can be induced to differentiate into bone, adipose, cartilage, muscle, and endothelium if these cells are cultured under specific permissive conditions [1, 2]. In rodents, a specific type of MSC (termed multipotent adult progenitor cell) can be isolated from bone marrow (BM) and contributes to most somatic cell types when injected into early blastocysts at the single-cell level [3]. Because MSCs have unique immunologic characteristics that suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [4], persistence in a xenogeneic environment is favored [1]. With such multiple differentiation capacities and unique immunoregulatory features plus self-renew potential [5], MSCs show promise as a possible therapeutic agent. Data from preclinical transplantation studies suggested that MSC infusions not only prevent the occurrence of graft failure but also have immunomodulatory effects [6].

MSCs are a rare population (approximately 0.001%–0.01%) of adult human BM [7]. Moreover, numbers of BM MSCs significantly decrease with age [8]. MSCs are also relatively few in adult peripheral blood [9] and in term cord

Correspondence: Yumi Fukuchi, Ph.D., Division of Cellular Therapy, The Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Telephone: 81-3-5449-5759; Fax: 81-3-5449-5453; e-mail: yfukuchi@ims.u-tokyo.ac.jp Received June 6, 2003; accepted for publication March 23, 2004. ©AlphaMed Press 1066-5099/2004/$12.00/0

blood [10]. A recent study showed that the population of MSC-like cells exists within the umbilical vein endothelial/subendothelial layer [11]. Furthermore, MSCs are present in fetal organs, such as liver, BM, and kidney, and circulate in the blood of preterm fetuses [10, 12, 13]. However, fetal samples can be difficult to procure, and term cord blood compared with preterm is a poor source of MSCs [10–12]. Such being the case, searching for appropriate sources, avoiding ethical issues, and establishing suitable culture systems are a challenge.

In this study, we evaluated the possibility that MSCs or cells with MSC-like potency are present in the human term placenta, and we obtained evidence that cells with the phenotype of MSCs exist in this tissue.

Materials and Methods

Isolation and Culture of Placenta-Derived Cells

Term placentas ($n = 57$; clinically normal pregnancies, caesarean section) were collected after obtaining written informed consent from donors to the Tokyo Cord Blood Bank.

The internal area (approximately 1 cm^3) of central placenta lobules was minced, hemolyzed, trypsinized (37°C for 5 minutes), and finally prepared in both single-cell suspensions and small digested residues. These samples were cultured with α-minimum essential medium (MEM; Sigma-Aldrich Co., St. Louis, http://www.sigmaaldrich.com) and supplemented with 15% fetal bovine serum (FBS; HyClone Laboratories, Logan, UT, http://www.hyclone.com), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Paisley, U.K., http://www.invitrogen.com). Cultures were maintained at 37°C in a humidified atmosphere with 5% CO_2. Three to 5 days after initiating incubation, the small digested residues were removed and the culture was continued. Approximately 3 to 4 weeks later, there were some colonies that contained 50 or more fibroblast-like cells that were more than 50% confluent; they were then trypsinized using 0.05% trypsin (Invitrogen) and replated at a 1:4 dilution. Under the same conditions, placenta-derived cells were continued to culture.

Fluorescence In Situ Hybridization Analysis

Human X/Y chromosomes of placenta-derived cells (male, $n = 3$; female, $n = 3$; passages two and three) were cultured on silica-coating slides and examined using CEP X/Y DNA probe kits (Vysis, Inc., Downers Grove, IL, http://www.vysis.com) according to the manufacturer's instructions. The slides were scanned under a fluorescence microscope using a rhodamine/fluorescein isothiocyanate (FITC) filter for X/Y chromosomes and a UV filter for 4',6-diamidine-2'-phenylindole dihydrochloride–stained cell nuclei.

Fluorescence-Activated Cell Sorter Analysis

Frozen and thawed placenta-derived cells ($n = 3$, passages 9–12) were trypsinized and incubated with medium containing 15% FBS-2 mM EDTA (pH 8.0) for 3 hours. Next the cells were stained with anti-human specific antibodies CD45-phycoerythrin (PE), CD31-PE, CD54-PE, CD29-FITC or CD29-PE, CD44-FITC or CD44-PE (BD Pharmingen, San Diego, http://www.bdbiosciences.com), AC133/1-PE (Miltenyi Biotec GmbH, Germany, http://www.miltenyibiotec.com), or PE- or FITC-conjugated isotype control (BD Biosciences, San Jose, CA, http://www.bd.com). After staining, cells were analyzed using fluorescence-activated cell sorter (FACS) Calibur flow cytometry (Becton, Dickinson, Mountain View, CA).

RNA Extraction and Reverse Transcription–Polymerase Chain Reaction

Total RNA from 10^5–10^6 placenta-derived cells ($n = 15$, passages 2–18, including frozen and thawed samples) was isolated using ISOGEN (Nippon Gene, Tokyo). RNA extracts were treated with deoxyribonuclease I (Amplification Grade, Invitrogen) for digesting contaminated genomic DNA.

Reverse transcription (RT) reactions were carried out on 1 μg of total RNA using the ThermoScript™ RT–polymerase chain reaction (PCR) system (Invitrogen), and 40 cycles of PCR were run using the Platinum PCR SuperMix (Invitrogen) according to the manufacturer's instructions. Evaluation of all PCRs was estimated using appropriate human tissue RNA (Clontech Laboratories, Inc., Palo Alto, CA, http://www.clontech.com), human BM-derived MSCs (Bio Whittaker, Inc., Walkersville, MD), and human cell lines [14, 15]. cDNA synthesis and genomic DNA contamination were examined using HOXB4 primers, which give products of 268 bp and 1.1 kb when amplifying cDNA and genomic DNA, respectively. Human-specific primers used were as follows: Oct-4 (866 bp), CCGCCGTATGAGTTCT GTGG/AGAGTGGTGACAGAGACAGG; Rex-1 (449 bp), ATGGCTATGTGTGCTATGAGC/CCTCAACTTCTAGT GCATCC; HOXB4 (268 bp), CTACCCCTGGATGCG CAAAG/CGAGCGGATCTTGGTGTTGG; CBFβ (300 bp), TCGTGCCCGACCAGAGAAGC/TCAGAATCATGGGA GCCTTC; β2-microglobulin (341 bp), GAGTGCTGTCTC CATGTTTG/TAACCACAACCATGCCTTAC; GATA-2 and Tie-2 [16]; TAL-1 [17]; CD34, AC133, flk-1, myogenin,

nestin, and α-1-fetoprotein [18]; flt-1 [19]; Nkx2.5 and GATA-4 [20]; renin and albumin [21]; GFAP [22]; and amylase and insulin [23].

Differentiation Studies

Passage 2 through 11 placenta-derived cells, including frozen and thawed samples ($n = 8$), were cultured either in an osteogenic (0.1 μM dexamethasone, 10 mM β-glycerol phosphate, 50 μM ascorbate) or adipogenic (1 μM dexamethasone, 5 μg/ml insulin, 0.5 mM isobutylmethylxanthine, 60 μM indomethacin) medium (all chemicals from Sigma) [10] on two-well Permanox slides (Nalge Nunc International, Naperville, IL). After 2 weeks, osteogenic differentiation was evaluated after 1% Alizarin Red S (Sigma) staining, and adipogenic differentiation was assessed using Oil Red O (Sigma) staining [2].

Subcloning and Characterization of Placenta-Derived Clones

The MSCV-IRES-GFP retroviral plasmid was transfected in PLAT-A packaging cells. Retroviral supernatants were collected and infected in No. 40 placenta-derived cells (passage five). The green fluorescent protein (GFP)–positive cells (passage seven) were sorted by FACS Vantage flow cytometry (Becton, Dickinson) and then subcultured at 5 or 10 cells per well (passage nine). After subcloning, we selected single retroviral-inserted subclones by Southern blot analysis using a GFP cDNA probe. Two clones were obtained, and then we carried out a FACS and RT-PCR analysis and differentiation studies for characterization of these clones.

Results

Characterization of Placenta-Derived Cells

Searching for alternative sources of MSCs, we attempted to prepare human term placentas and isolated fibroblast-like cells from every placenta isolation ($n = 57$; Fig. 1). In a single-cell suspension culture of the isolated placenta, cells firstly formed colony-forming unit fibroblast (CFU-F)–like colonies (Figs. 1A, b). On the other hand, in the culture of small trypsin-digested residues of placenta, cells began to migrate and proliferate (data not shown). After the first passage, cells from both samples expanded in the same monolayer manner (Fig. 1A, a–c). Cord blood (CB) is a rich source of hematopoietic stem cells and MSCs, and the term placenta contains much CB, primarily adherent cells derived from freshly isolated CB mononuclear cells ($n = 77$). However, CBs were obtained (after receiving the informed consent from Kiyosenomori Hospital, Tokyo) but did not survive in α-MEM containing 15% FBS. To determine whether these cells were from maternal or fetal parts of the placenta, we did a fluorescence in situ hybridization analysis using X- and Y-probes. These cells were positive for X- and Y-signals, indicating that they were from a fetal part of the placenta (Fig. 1B). The placenta-derived cells were classified into two groups according to growth characteristics; one could proliferate more than 20 passages (Fig. 1C, Nos. 40 and 29), and the other went into replicative senescence between 10 and 20 passages (Fig. 1C, Nos. 41 and 44). The former type had a small and homogeneous morphology, but the latter type was of a bigger shape than the former. We also examined the surface marker profile of the above three representative placenta-derived cell lines using FACS, and these three lines had a similar phenotype, as follows: $CD45^{low}CD31^{-}AC133^{-}CD54^{+}CD29^{+}CD44^{+}$ (Fig. 1D), which closely resembles the phenotypes of BM-derived and CB-derived MSCs [2, 7, 10, 24].

Gene Expression Patterns of Placenta-Derived Cells

For a closer study of placenta-derived cells, we did a RT-PCR analysis for various genes, including stem cell markers, hematopoietic/endothelial cell–related genes, and organ-specific genes. The placenta-derived cells expressed many of the genes derived from mesoderm, ectoderm, and endoderm (Fig. 2). Additionally, expression patterns of stem cell markers and hematopoietic/endothelial cell–related genes in placenta-derived cells were similar to those of human BM (hBM)–derived MSCs (Fig. 2, lane 2).

Differentiation Potential of Placenta-Derived Cells

To estimate the potential to differentiate into osteoblasts and adipocytes, the placenta-derived cells were cultured in osteogenic or adipogenic medium. At the end of the induction periods, most of the cells were Alizarin Red S–positive (Figs. 3B, 3C) or Oil Red O–positive (Figs. 3E, 3F), indicating differentiation to osteoblasts or adipocytes, respectively. In contrast, cells cultured with regular medium were not significantly stained (Figs. 3A, 3D). Such data indicate that the placenta-derived cells had bidirectional differentiation potency.

Subcloning of Placenta-Derived Cells

The placenta-derived cells used in the above experiments are obviously heterogeneous and may be a mixture of progenitors that can differentiate into specific lineages. To



Figure 1. Isolation and characterization of placenta-derived cells. **(A):** Morphology of placenta-derived cells. Cells from a single-cell suspension easily expanded through the formation of colony-forming unit fibroblast–like colonies. a: 10 days after isolation (× 100 magnification); b: 3 weeks after isolation (× 40 magnification); c: 6 weeks after isolation (passage 3; × 40 magnification). **(B):** Fluorescence in situ hybridization analysis for human X/Y chromosomes. Cells from male placenta have Y-positive (green) and X-positive (orange) signals. **(C):** Growth curve of placenta-derived cells. Frozen and thawed cells ($n = 4$, started at passage six or seven) were seeded at 0.5×10^5 cells per well and cultured until 90% confluence was reached. These cells were resuspended, enumerated, and reseeded at the same density for 10 days. **(D):** Immunophenotype of placenta-derived cells. Cells were stained with phycoerythrin-conjugated or fluorescein isothiocyanate–conjugated antibodies against CD45, CD31, AC133, CD54, CD29, CD44, or immunoglobulin isotype control antibodies. Cells were analyzed using fluorescence-activated cell sorter Calibur. Individual placenta-derived cells were given serial numbers of placenta isolation. Representative samples were used for these figures. **(Figure 1 D continued on next page.)**



Figure 1 (continued).

exclude this possibility, we attempted to subclone No. 40 placenta-derived cells showing the human MSC (hMSC)–like gene expression pattern using RT-PCR (Fig. 2, lanes 2 and 7). We established two clones, B2 and F4 (Fig. 4A, lanes 1 and 9), which retained almost all of the phenotypes of their parental cells; surface marker expression (CD45^{low}CD31^{-}AC133^{-}CD54^{+}CD29^{+}CD44^{+}), gene expression patterns, and differentiation potential (Figs. 4B–4D versus Figs. 1–3). Moreover, these phenotypes were similar to those of other placenta-derived cell lines. Such data suggest that although the placenta-derived cells are considered to be polyclonal, most of the clones are similar in gene-expression profiles and retain the differentiation capacity to osteoblasts and adipocytes.

Discussion

In this study, we successfully isolated placenta-derived cells from human term placentas ($n = 57$) and then characterized morphology, cell-surface antigens, gene expression patterns, and differentiation capacity of these cells. Results of RT-PCR analysis of 15 individual placenta-derived cells showed that the expression patterns of seven genes (HOXB4, CD34, AC133, flk-1, Tie-2, GATA-4, and myogenin) varied but expressions of 14 other genes were quite similar (Fig. 2



Figure 2. Gene expression patterns of placenta-derived cells. Placenta-derived cells were characterized using reverse transcription–polymerase chain reaction. Samples are as follows: lane 1, noncultured placenta (trypsin-digested residue); lane 2, human bone marrow–derived mesenchymal stem/progenitor cells; lanes 3–7, placenta (Nos. 29, 41, 42, 44, and 40)-derived cells; lane 8, reagent control; lane 9, positive control (i.e., Oct-4, Rex-1, HOXB4, and β2-microglobulin were used for EoL-3. GATA-2, CBFβ, TAL-1, CD34, AC133, flk-1, and flt-1 were used for TF-1. NKx2.5 and GATA-4 were used for human heart RNA. Renin and myogenin were used for human kidney RNA and skeletal muscle RNA, respectively. Nestin and GFAP were used for human brain RNA. α-1-fetoprotein and albumin were used for human liver RNA. Amylase and insulin were used for human pancreas RNA). In this figure, we took up the data from the five representative placenta-derived cells, and each of placenta-derived cells was shown by serial numbers of placenta isolation.

shows evidence of six placenta-derived cells; nine are not shown). These expression patterns resemble those of hBM-derived MSCs, except for renin and flt-1 (Fig. 2, lane 2). Comparison of the two types of placenta-derived cells with distinct growth characteristics (one that propagates more than 20 passages [Fig. 1C, Nos. 40 and 29] and the other with growth limitation [Nos. 41, 42, and 44]) showed that the expressions of HOXB4, CD34, Tie-2, and GATA-4 were different among these groups. The former more resembled the hBM-derived MSCs for gene expression patterns (Fig. 2). Collectively, these results indicate that the placenta-derived cells have MSC-like gene expression patterns. In addition, they showed a differentiation capacity toward both osteoblasts and adipocytes (Fig. 3), suggesting that these cells have MSC-like differentiation potential.

Because the original culture of 57 placenta-derived cell lines should be a mixture of a variety of cell types, we attempted to subclone these cells to do a detailed analysis.



Figure 3. Differentiation potential of placenta-derived cells. After a 2-week culture in osteogenic (**B, C**) or adipogenic (**E, F**) medium or regular medium (**A, D**), each of the placenta-derived cells was evaluated for osteogenic or adipogenic differentiation using specific staining and hematoxylin counterstaining. Magnification: A, B, D, E, ×40; C, F, ×100. A representative sample was used for this figure.

Two established clones retained almost all of the phenotypes of parental No. 40 placenta-derived cells, including morphology, cell-surface populations, gene expression patterns, and differentiation capacity. However, these clones also had some differences in mRNA expression, such as CD34 and α-1-fetoprotein. These genes were upregulated compared with the parent mixture cells (Figs. 2, 4C). In some reports, small proportions of hMSCs expressed low levels of CD34 [6, 25]. Further experiments are required to determine the meaning of expressions of these genes.

Rex-1 is known to be important for maintaining undifferentiated embryonic stem cells [26, 27]. However, the role of this gene in MSCs is not clear. The result of RT-PCR analysis showed that Rex-1 is expressed in both BM-derived MSCs and placenta-derived cells (Fig. 2) but not in the two clones (Fig. 4C). Analysis of parental placenta-derived cells at various time points during passages (passages 3, 5, 9, and 18 for original cells; passages 13 and 26 for GFP-labeled mixture cells) using RT-PCR showed that only Rex-1 expression switched from positive (before passage 5, Fig. 2) to negative (after passage 9; data not shown). Additional analysis is required to know the role of Rex-1 in placenta-derived cells.

Interestingly, cell-surface markers analyzed using FACS revealed that the placenta-derived mixture cells and clones had the $CD45^{low}CD31^{-}AC133^{-}CD54^{+}CD29^{+}CD44^{+}$ phenotype (Figs. 1D, 4B), and the expression of CD45 and AC133 antigens differed from MSCs derived from other sources [2, 7, 10, 24]. As for the expression of AC133, the results were negative with FACS yet positive with RT-PCR analysis. This contradictory finding may be due to a damaged AC133 epitope by trypsin treatment of the cells. As for the expression of CD45, some reports showed that unprocessed or fresh MSCs were $CD45^{med,low}$, whereas cultured MSCs and more mature cells were $CD45^{-}$ [24, 28]. However, as our results showed, the expression of CD45 was low during passages. The $CD45^{low}$ phenotype might be one of the specific characteristics of the placenta-derived cells.

This study showed that the placenta-derived MSC-like cells could be easily isolated and expanded without morphological and characteristic changes in medium supplemented only with FBS. Therefore, the placenta may prove to be an attractive and rich source of MSCs. Further studies are required to better understand the precise nature of placenta-derived cells and to explore their potential clinical applications.

Acknowledgments

We thank Drs. T. A. Takahashi and N. Watanabe (Division of Cell Processing, Institute of Medical Science, The University of Tokyo, Japan) for significant advice on these placenta-derived cells; Dr. Y. Koshino and Ms. M. Ito (Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Japan) for advice and technical support; and Drs. H. Funabiki and S. Akutsu (Kiyosenomori Hospital, Japan) for assistance with cord blood collections.



Figure 4. Establishment and characterization of two clones from No. 40 placenta-derived cells. **(A):** Establishment of placenta-derived clones. No. 40 placenta-derived cells were transduced with MSCV-IRES-GFP retrovirus, and green fluorescent protein (GFP)-positive population was sorted by fluorescence-activated cell sorting, then replated onto a 96-well dish at 5 or 10 cells per well and expanded. DNAs from these GFP-positive No. 40 placenta-derived subclones were digested overnight with BamHI (cut only once in the MSCV-IRES-GFP plasmid), and fragments were separated by electrophoresis and probed with a 32P-labeled GFP cDNA probe. Samples are as follows for lanes 1-6, 8, and 9: subclones B2, B4, D2, D3, E4, G3, F1, and F4, respectively. These subclones were obtained from subcloning of five cells per ell. Lanes 7 and 10, subclones E4 and G4. (Figure 4C and D continued on next page.) **(Figure 4 C and D continued on next page.)**





Figure 4. Establishment and characterization of two clones from No. 40 placenta-derived cells. **(A):** Establishment of placenta-derived clones. No. 40 placenta-derived cells were transduced with MSCV-IRES-GFP retrovirus, and green fluorescent protein (GFP)-positive population was sorted by fluorescence-activated cell sorting, then replated onto a 96-well dish at 5 or 10 cells per well and expanded. DNAs from these GFP-positive No. 40 placenta-derived subclones were digested overnight with BamHI (cut only once in the MSCV-IRES-GFP plasmid), and fragments were separated by electrophoresis and probed with a 32P-labeled GFP cDNA probe. Samples are as follows for lanes 1-6, 8, and 9: subclones B2, B4, D2, D3, E4, G3, F1, and F4, respectively. These subclones were obtained from subcloning of five cells per ell. Lanes 7 and 10, subclones E4 and G4. (Figure 4C and D continued on next page.) **(Figure 4 C and D continued on next page.)**

References

1 Liechty KW, MacKenzie TC, Shaaban AF et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282–1286.

2 Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001;98:2615–2625.

3 Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;20:1–9.

4 Bartholomew A, Sturgen C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42–48.

5 Gerson SL. Mesenchymal stem cells: no longer second class marrow citizens. Nat Med 1999;5:262–264.

6 Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000;28:875–884.

7 Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–147.

8 Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Aging Dev 2001;122:713–734.

9 Zvaifler NJ, Marinova-Mutafchieva L, Adams G et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000;2:477–488.

10 Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235–242.

11 Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003;21:105–110.

12 Campagnoli C, Roberts IAG, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396–2402.

13 Almeida-Porada G, Shabrawy D, Porada C et al. Differentiative potential of human metanephric mesenchymal cells. Exp Hematol 2002;30:1454–1462.

14 Kitamura T, Tange T, Terasawa T et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989;140:323–334.

15 Hosoda M, Makino S, Kawabe T et al. Differential regulation of the low affinity Fc receptor for IgE (Fc epsilon R2/CD23) and the IL-2 receptor (Tac/p55) on eosinophilic leukemia cell line (EoL-1 and EoL-3). J Immunol 1989; 143:147–152.

16 Levenberg S, Golub JS, Amit M et al. Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2002;99:4391–4396.

17 Kaufman DS, Hanson ET, Lewis RL et al. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2001;98:10716–10721.

18 Shamblott MJ, Axelman J, Littlefield JW et al. Human embryonic germ cell derivatives express a broad range of developmentally distinct markers and proliferate extensively in vitro. Proc Natl Acad Sci U S A 2001;98:113–118.

19 Bellamy WT, Richter L, Frutiger Y et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728–733.

20 Kehat I, Kenyagin-Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001;108:407–414.

21 Schuldiner M, Yanuka O, Itskovitz-Eldor J et al. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2000;97:11307–11312.

22 Vescovi AL, Parati EA, Gritti A et al. Isolation and cloning of multipotential stem cells from the embryonic human CNS and establishment of transplantable human neural stem cell lines by epigenetic stimulation. Exp Neurol 1999;156:71–83.

23 Zulewski H, Abraham EJ, Gerlach MJ et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 2001;50:521–533.

24 Reyes M, Dudek A, Jahagirdar B et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337–346.

25 Deschaseaux F, Gindraux F, Saadi R et al. Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their $CD45^{med,low}$ phenotype. Br J Haematol 2003;122:506–517.

26 Ben-Shushan E, Thompson JR, Gudas LJ et al. Rex-1, a gene encoding a transcription factor expressed in the early embryo, is regulated via Oct-3/4 and Oct-6 binding to an octamer site and a novel protein, Rox-1, binding to an adjacent site. Mol Cell Biol 1998;18:1866–1878.

27 Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation or self-renewal of ES cells. Nat Genet 2000;24:372–376.

28 Clark E, Wognum AW, Marciniak R et al. Mesenchymal cell precursors from human bone marrow have a phenotype that is direct from cultured mesenchymal cells and are exclusively present in a small subset of $CD45^{lo}$ $SH2^{+}$ cells. Blood 2001;98:85a.

Viral Infections in Juvenile Myelomonocytic Leukemia: Prevalence and Clinical Implications

Atsushi Manabe, MD,† Tetsu Yoshimasu, MD,* Yasuhiro Ebihara, MD,* Hiroshi Yagasaki, MD,* Mika Wada, MD,* Kumiko Ishikawa, MD,* Junichi Hara, MD,‡ Kenichi Koike, MD,§ Hiroshi Moritake, MD,¶ Yong Dong Park, MD,‖ Kohichiro Tsuji, MD,* Tatsutoshi Nakahata, MD** for the MDS Committee of the Japanese Society of Pediatric Hematology*

Objectives: Viral infections may complicate the diagnosis of juvenile myelomonocytic leukemia (JMML) in a substantial proportion of patients, but this possibility has not been tested in a prospective study. The authors therefore measured the cellular expression of the MxA protein, a reliable marker of viral infection, at diagnosis in children with JMML to estimate the prevalence of such infections.

Methods: Eighteen children, aged 1 to 69 months, who met the diagnostic criteria of the International JMML Working Group were prospectively studied. MxA expression was assessed by flow cytometric analysis of peripheral blood mononuclear cells stained with an anti-human MxA antibody. All data were obtained through the MDS Committee of the Japanese Society of Pediatric Hematology.

Results: Twelve patients (67%) had elevated levels of the MxA protein, with rotavirus, RS virus, or CMV infection documented in three of these patients. Although none of the patients had primary Epstein-Barr virus (EBV) infection, reactivation of the virus was strongly suspected in four children, including two with monosomy 7, each having increased levels of MxA. Southern blot analysis revealed monoclonal integration of the EBV genome into bone marrow mononuclear cells from one of these patients. There was no discernible correlation between increases in the marker protein and the presenting features or course of the disease.

Conclusions: Viral infection may be present in two thirds of children with newly diagnosed JMML, but it does not constitute a basis for revising clinical management. The possibility that EBV or other viruses contribute to JMML pathogenesis by stimulating pre-exiting malignant clones warrants further investigation.

Key Words: juvenile myelomonocytic leukemia, viral infections, monosomy 7, Epstein-Barr virus, MxA

(*J Pediatr Hematol Oncol* 2004;26:636–641)

Received for publication December 13, 2003; accepted July 12, 2004.

From the *Department of Pediatric Hematology-Oncology, Institute of Medical Science, University of Tokyo, Tokyo; †Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan; ‡Department of Pediatrics, Osaka University, Osaka, Japan; §Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan; ¶Department of Pediatrics, Miyazaki Medical College, Miyazaki, Japan; ‖Department of Pediatrics, Nara Medical University, Nara, Japan; and **Department of Pediatrics, Kyoto University, Kyoto, Japan.

Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Reprints: Atsushi Manabe, MD, Department of Pediatrics, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan (e-mail: manabe-luke@umin.ac.jp).

Copyright © 2004 by Lippincott Williams & Wilkins

Juvenile myelomonocytic leukemia (JMML), previously described as juvenile chronic myelocytic leukemia or chronic myelomonocytic leukemia,[1,2] is a rare disease with a generally ominous prognosis. Niemeyer et al[3] reported a 10-year survival rate of 39% for patients who underwent hematopoietic stem cell transplantation (HSCT), compared with only 6% for patients who did not receive this treatment. Thus, allogeneic HSCT is recommended for most children with JMML.[4–8]

A consensus on the diagnosis of JMML was reached only recently. The World Health Organization collaborative study group classified JMML as a disease having characteristics of both myelodysplastic syndrome (MDS) and myeloproliferative disorders,[9] while the International JMML Working Group introduced a new set of diagnostic criteria that combine suggestive clinical observations with major and minor laboratory findings (Table 1).[10] Although this revised approach to the diagnosis of JMML has gained wide acceptance, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or human herpesvirus-6 infection can produce signs and symptoms closely resembling those seen in patients with JMML, leading some investigators to suggest that documentation of a viral infection in a child with suspected JMML should raise questions regarding the diagnosis of a malignant disease.[11–13]

It was previously shown that MxA protein is specifically expressed in circulating mononuclear cells in response to stimulation by type I interferons in the presence of viral infections.[14–22] We therefore prospectively studied the peripheral blood mononuclear cells of children with newly diagnosed JMML for evidence of viral infection, using cytoplasmic expression of the MxA protein as a surrogate marker, and then

TABLE 1. Diagnostic Criteria for JMML

Suggestive clinical features
1. Hepatosplenomegaly
2. Lymphadenopathy
3. Pallor
4. Fever
5. Skin rash

Major laboratory criteria (all three required)
1. No Philadelphia chromosome; or no BCR-ABL rearrangement
2. Peripheral blood monocyte count >1 × 10^9/L
3. Bone marrow blasts >20%

Minor laboratory criteria (minimum of two required)
1. Increased fetal hemoglobin, corrected for age
2. Myeloid precursors evident on peripheral blood smear
3. White blood cell count >10 × 10^9/L
4. Clonal abnormalities, including monosomy 7
5. GM-CSF hypersensitivity of myeloid progenitors in vitro

Adapted from Niemeyer et al.[10]

related the findings to the clinical course and presenting features of the disease.

METHODS

Patients

Eighteen children with an established diagnosis of JMML were enrolled in the study. Clinical data and samples for laboratory analysis were obtained through the MDS Committee of the Japanese Society of Pediatric Hematology.[23] Informed consent was given by the guardians of the patients. Age at diagnosis ranged from 1 to 69 months (median 15 months); follow-up for the surviving patients ranged from 4 to 33 months (median 12 months). There were 12 boys and 6 girls. One patient had neurofibromatosis 1 (NF-1) and another had Noonan syndrome. This study was approved by the MDS Committee of the Japanese Society of Pediatric Hematology.

MxA Protein Expression in Lymphocytes

The expression of MxA was tested in blood samples (1 mL heparinized venous blood) collected at diagnosis. After separation on a Ficoll-Metrizamide density gradient (Lymphoprep; Nyegaad, Oslo, Norway), the mononuclear cells were washed and resuspended in alpha-MEM (Gibco, NY) supple-

TABLE 2. Clinical and Laboratory Characteristics of the Patients

Patient No.*	Age (mo)	Sex	Clinical Features†	Minor Criteria†	Karyotype	Spontaneous Colony Formation	CRP (mg/dL)	Other Conditions
1	1	F	4	1,2,3,5	Normal	+	4.1	
2	1	M	1	2,3,5	Normal	+	1.6	
3	3	M	1,2,3,4	1,2,3	Normal	+	2.8	
4	6	M	1,3,4	2,3	Normal	+	0.2	
5	8	M	1,2,3	2,3,5	Normal	−	1.7	
6	16	M	1,3,4	2,3,4,5	−7	+	0.9	
7	24	M	1,2,5	1,2,3,5	Normal	+	0.0	
8	24	F	1,2	1,2,3,5	Normal	+	0.2	
9	28	M	1,2,5	1,3	Normal	+	1.6	
10	37	M	1,2,3,4	1,2,3,4	−7	−	1.7	
11	37	F	1,2,4,5	1,2,3	Normal	+	3.0	
12	69	M	1,4	3,4,5	−7	+	3.5	NF-1
13	1	F	1,2,3	1,2,3,5	Normal	−	3.3	
14	2	M	1	1,2,3	Normal	+	4.8	NS
15	4	F	1,2,4	1,2,3,4,5	t(2;19)	+	0.3	
16	13	M	1,2	1,2,3	Normal	+	1.6	
17	32	M	1,2,3,4,5	1,2,3,4,5	8+, −Y	+	3.1	
18	56	F	1,3,4	1,2,3	Normal	−	0.6	

All patients met major criteria: lack of the Philadelphia chromosome (or no BCR-ABL rearrangement), peripheral blood monocyte count >1 × 10^9/L, and bone marrow blasts <20%.

CRP, C-reactive protein (normal value <1 mg/dL); NF-1, neurofibromatosis-1; NS, Noonan syndrome.

*Patients with MxA protein level greater than 2.0 FI are indicated by boldface type.

†Numbers correspond to diagnostic guidelines listed in Table 1.

© 2004 Lippincott Williams & Wilkins

mented with 10% FCS (HyClone, Logan, UT). The cytoplasmic staining technique has been described.[24] Briefly, the cells were fixed and their membranes permeabilized with Fix and Perm (An Der Grub, Austria), followed by staining with antihuman MxA antibody (KM1135, a mouse monoclonal antibody, IgG1 isotype, donated by Kyowa Co., Tokyo, Japan). Mouse IgG1 (DAKO) served as a control, and PE-labeled goat antimouse IgG (DAKO) was used as a secondary antibody. The expression of MxA protein in mononuclear cells in a lymphoid gate was analyzed by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA).

As a measure of the intensity of staining, we used a fluorescence index (FI), representing the ratio of the fluorescence intensity of cells stained with the antihuman MxA antibody versus that of cells stained with the isotype-matched control. In some experiments, the mononuclear cells were incubated in complete medium with 1,000 U/mL of interferon-alpha (IFN-α; INTRON A, Schering Corp.) at 37°C for 4 hours before cytoplasmic staining was performed. In a previous study,[14] we showed that the FI of MxA in virus-infected patients ranged from 2.6 to 38.9 (median 6.7), contrasted with 0.9 to 2.0 (median 1.2) in control subjects without fever ($P < 0.05$, Mann-Whitney test). Hence, an FI of 2.0 was selected as the threshold value for the diagnosis of viral infections.

Southern Blot Hybridization

The clonality of EBV infection was determined by Southern blotting with a terminal repeat probe, as previously described.[25] Genomic DNA extracted from bone marrow was digested with *Eco*RI, subjected to gel electrophoresis, transferred to a nylon membrane, hybridized with a ^{32}P-labeled *Bam*HI-W fragment from the terminal region of EBV, and visualized by autoradiography.

RESULTS

All 18 patients fulfilled the diagnostic criteria of the International JMML Working Group, although the constellation of features varied widely (Table 2). Seventeen patients had hepatosplenomegaly, 11 had lymphadenopathy, 8 had pallor, 10 had a temperature of more than 38°C, and 4 had skin rash. Among the minor laboratory criteria (a minimum of two required), an elevated hemoglobin F level was noted in 13 patients, myeloid precursors on a peripheral blood smear in 16, a white blood cell count above 10×10^9/L in 18, a clonal chromosomal abnormality in 5, and hypersensitivity of myeloid progenitor cells to granulocyte/macrophage colony-stimulating factor (GM-CSF) in vitro in 10 of 16 evaluable patients. Myeloid precursors from 14 patients showed spontaneous colony-forming ability in vitro.

TABLE 3. Results of MxA Expression Analysis and Serologic Tests

Patient No.*	MxA (no IFN-α) (FI)	MxA (with IFN-α) (FI)	CMV Titer	EBV Titer	Other Virus
1	5.2	NT	IgM−, IgG−	EBNA 20, VCA-IgG 80	
2	2.8	NT	IgM+, IgG+	EBNA <10, VCA-IgG <10	
3	2.3	2.4	IgM−, IgG+	EBNA <10, VCA-IgG <10	Rota
4	2.1	4.5	IgM−, IgG−	EBNA <10, VCA-IgG <10	
5	2.1	NT	IgM−, IgG+	EBNA <10, VCA-IgG <10	
6	4.0	2.7	IgM−, IgG+	EBNA 40, VCA-IgG 2560	
7	8.1	3.8	IgM−, IgG+	EBNA+, VCA-IgG+	
8	8.5	NT	IgM−, IgG−	EBNA <10, VCA-IgG <10	RS
9	3.3	6.3	IgM−, IgG−	EBNA 10, VCA-IgG 640	
10	4.4	NT	IgM−, IgG+	EBNA+, VCA-IgG+	
11	2.2	4.4	IgM−, IgG+	EBNA 40, VCA-IgG 320	
12	14.0	NT	IgM−, IgG−	EBNA 40, VCA-IgG 320	
13	1.7	4.0	IgM−, IgG−	EBNA <10, VCA-IgG <10	
14	1.0	1.8	IgM−, IgG−	EBNA <10, VCA-IgG <10	
15	1.0	1.2	IgM−, IgG−	EBNA <10, VCA-IgG <10	
16	1.9	4.5	IgM−, IgG+	NT	
17	1.2	NT	IgM−, IgG−	EBNA <10, VCA-IgG <10	
18	1.2	3.4	IgM−, IgG+	EBNA 40, VCA-IgG+	

FI, fluorescence index; NT, not tested; VCA, viral capsid antigen; EBNA, Epstein-Barr virus nuclear antigen; RS, respiratory syncytial.

*Patients with increased MxA expression (FI > 2.0) are denoted by boldface type.

VCA-IgM was negative in all patients.

© 2004 Lippincott Williams & Wilkins

Karyotypic abnormalities included monosomy 7 in three patients, the chromosomal translocation t(2;19) in one, and trisomy 8 with loss of the Y chromosome in one. Three patients had clinically apparent viral infections (rotavirus, respiratory syncytial virus, and CMV). Serologic studies for CMV and EBV were performed in all but one patient (Table 3). The results were not diagnostic of primary EBV infection but indicated reactivation of EBV in four patients (patients 6, 9, 11, and 12), including two with monosomy 7.

Analysis of MxA Protein Expression and EBV Clonality

The expression of MxA in peripheral blood mononuclear cells was increased (>2.0 FI) in 12 patients (see Table 3). This finding extended to each of the three patients with monosomy 7, including the patient with NF-1, but not to those with other karyotypic abnormalities or to the child with Noonan syndrome. MxA protein levels greater than 2.0 FI did not correlate with age at diagnosis, the presence of fever, the serum level of C-reactive protein, or any of the other presenting features determined in this study. As expected, each of the three patients with clinically apparent viral infection had an increased FI value.

The MxA level was also elevated in the four patients with apparent EBV reactivation, prompting us to analyze the clonality of these cases, using a probe derived from EBV terminal repeats. Southern blotting showed monoclonal integration of the EBV genome into the bone marrow mononuclear cells of patient 6 (Fig. 1) but not of patients 11 and 12 (not shown).



FIGURE 1. EBV-DNA analysis. A DNA sample from patient 6 was digested with *Eco*RI and hybridized with a probe recognizing the termini of the EBV genome. N, normal control; P, patient sample; PC, positive control (Raji cell line). A single 3.0-kb band indicates monoclonal integration of EBV into the patient's DNA.

Since MxA expression is specifically induced by IFN-α, we considered that lymphocytes from some patients with JMML might lack the ability to respond to the cytokine. Table 3 shows the FI values for 11 patients whose blood mononuclear cells were stained with antihuman MxA antibody after IFN-α stimulation in culture. In nine of these patients, the values were higher in stimulated mononuclear cells than in unstimulated cells. One of the two exceptions was patient 14, who had Noonan syndrome; the other was patient 15, whose myeloid progenitor cells carried the t(2;19). These results suggest that low expression of MxA (<2.0 FI) in unstimulated cells simply reflects the lack of interferon production in vivo rather than any intrinsic defect of mononuclear cells that might block responsiveness to IFN-α.

Clinical Outcome

All patients were managed clinically according to a single protocol developed by the authors under the auspices of the MDS Committee of the Japanese Society of Pediatric Hematology. Two patients, one with documented CMV infection (patient 2) and the other with an increased FI but no specific virus (patient 4), had spontaneous regression of all disease (Table 4). In patient 2, the CMV genome was detected in the blood and the signs of JMML disappeared without specific treatment. In patient 4, the clinical characteristics of the disease resolved within 3 months while the child was awaiting transplantation. Of the remaining 16 patients, 10 underwent allogeneic HSCT, 3 received chemotherapy only, and 3 were not treated because of early complications, including leukemic cell infiltration to the lungs and congestive heart failure associated with Noonan syndrome. Seven of the 10 patients who received a transplant remain in complete hematologic remission for 8+ to 26+ months (median 17+ months). Three patients are awaiting allogeneic HSCT.

DISCUSSION

MxA protein is specifically expressed in circulating mononuclear cells in response to stimulation by type I interferons.[15,16] Since the biologic half-life of IFN-α is very short (1–2 hours) but that of MxA is rather long (2.3–2.5 days),[17,26] detection of an elevated level of MxA soon after the onset of viral infection should be diagnostic, a prediction supported by

© 2004 Lippincott Williams & Wilkins